AstraZeneca has said it hopes to start distributing Oxford University’s Covid-19 vaccine by the end of 2020, says Samuel Lovett in The Independent. Preliminary trial results revealed that it induces a “strong immune response within humans” and “appears to be safe”. More detailed results for this vaccine are expected to be available between September and November. Meanwhile, the company has struck deals with the UK, France, Germany and the US to deliver supplies of the vaccine, and will start manufacturing it even before trials finish, with the aim of making two billion doses.
The results may be positive enough to continue with trials, but they “weren’t enough to convince the market”, says Bloomberg. AstraZeneca’s shares fell back early this week. Good news had been “widely expected”, while there are also concerns over whether its vaccine can match the progress seen at rival companies such as Pfizer, BioNtech SE and Moderna. The decision to prioritise a two-dose regime (rather than a single injection) and the fact that the end-of-year deadline is later than the previous promise of a September delivery are also “dampening” some of the enthusiasm.
Hedging bets
In a reminder that AstraZeneca is not the only company close to bringing a vaccine to market, even the British government, one of the biggest backers of Oxford University’s research, now seems to be hedging its bets by working with rivals, says The Daily Telegraph. Having previously agreed to buy 100 million doses of the AstraZeneca vaccine, it has signed additional deals to “secure 90 million doses of two possible Covid-19 vaccines from the Pfizer and BioNTech alliance and French group Valneva”. This could rise to 140 million doses if the Valneva vaccine proves to be “effective and suitable”.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Betting on vaccines from more than one company is an approach investors should adopt too, says Lex in the Financial Times. Formerly considered a “neglected Cinderella industry”, vaccines have “never been so hot”. But there are 170 Covid-19 vaccines in development, so many “also-rans” will inevitably suffer from “irrevocable losses”. Investors should back different approaches to “spread risk”. In any case, the need for “multiple success stories” means that this “is not a winner-takes-all market”, with rewards likely to be spread across multiple firms.
Investors should also note that even if they do manage to bet on a winner, “sales and profits might not flow as much as hoped”, says Charley Grant in The Wall Street Journal. Given that the drug industry will want to avoid “heavy scrutiny” over its pricing practices during the upcoming US election, it will be under pressure to price a vaccine “modestly”. More broadly, the “euphoric trading” that has seen the share price of biotech companies such as Moderna triple means that “caution is always warranted”.
-
Pensions IHT reform: major changes needed says former ministerExperts are calling on the government to make the system for applying inheritance to pensions ‘more effective, efficient and humane’
-
MoneyWeek turns 25: Vote for your favourite MoneyWeek cover in our pollPoll As MoneyWeek reaches an important milestone, we’re inviting readers to choose their favourite cover from over the years. Vote in our poll.
-
The Stella Show is still on the road – can Stella Li keep it that way?Stella Li is the globe-trotting ambassador for Chinese electric-car company BYD, which has grown into a world leader. Can she keep the motor running?
-
Global investors have overlooked these solid stocks going for growthOpinion Nisha Thakrar, investment specialist at Nedgroup Investments, selects three undervalued stocks with long-term growth potential
-
LVMH is set to prosper as the wealthy start shopping againAfter two years of uncertainty, the outlook for LVMH is starting to improve. Is now a good time to add the luxury-goods purveyor to your portfolio?
-
Japan is still rising to new highs – here's how to investOpinion Political ructions in Japan are no obstacle to gains, and the return of inflation may even benefit stocks, says Max King. What is Japan doing right?
-
Investors need to get ready for an age of uncertainty and upheavalTectonic geopolitical and economic shifts are underway. Investors need to consider a range of tools when positioning portfolios to accommodate these changes
-
Investing in UK universities: how to spin research into profitsUK universities are a vital economic asset, but they are also Britain's 'equivalent of Gulf oil.' There are opportunities here for investors
-
AI is a bet we’re forced to makeIt’s impossible to say yet if AI will revolutionise the world, but failure would clearly be very costly, says Cris Sholto Heaton
-
The MoneyWeek Wealth Summit 2025: how to invest for a volatile eraMoneyWeek's 25th birthday conference’s agenda offers investors a wide array of compelling themes
